Switzer Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -40.74%
- Profit Growth -45.97%
- Ebitda -109.76%
- Net Worth 12.21%
- Total Assets -19.84%
About Switzer Lifescience
Switzer Lifescience Private Limited (SLPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 March 2009 and has a history of 15 years and ten months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jiteenkumar Vadgama and Jayesh Patni serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24230GJ2009PTC056360
- Company No.
056360
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Switzer Lifescience Private Limited offer?
Switzer Lifescience Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antiepileptic Drugs, Gelatin Capsules, Soft Gelatin Capsules, Antibiotic Tablets & Capsules, Azithromycin Tablets, Multivitamin Tablets & Capsules, Antifungal Injection, Tablet & Syrup, Fluconazole Tablet, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Switzer Lifescience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jiteenkumar Vadgama  | Director | 16-Mar-2009 | Current |
| Jayesh Patni | Director | 16-Mar-2009 | Current |
Financial Performance of Switzer Lifescience.
Switzer Lifescience Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 40.74% decrease. The company also saw a substantial fall in profitability, with a 45.97% decrease in profit. The company's net worth Soared by an impressive increase of 12.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Switzer Lifescience?
In 2019, Switzer Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Switzer Lifescience?
Unlock and access historical data on people associated with Switzer Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Switzer Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Switzer Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.